{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:23:52Z","timestamp":1794709432139,"version":"4.9.1"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,15]]},"DOI":"10.2169\/internalmedicine.6453-25","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:08:16Z","timestamp":1768428496000},"page":"2216-2220","source":"Crossref","is-referenced-by-count":1,"title":["Acute Myocardial Infarction from Stent Thrombosis Following a Loss to Follow-up Triggered by Financial Barriers to PCSK9 Inhibitor Therapy"],"prefix":"10.2169","volume":"65","author":[{"given":"Tetsuro","family":"Nagao","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokio","family":"Nishiwaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Hori","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Ebuchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Okumura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Arai R, Hotsubo Y, Nakajima Y, et al. Impact of a physician-led strike early-strike strong lipid-lowering protocol incorporating PCSK9 inhibitors for patients with acute myocardial infarction. J Atheroscler Thromb 32: 1434-1446, 2025.","DOI":"10.5551\/jat.65731"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376: 1713-1722, 2017.","DOI":"10.1056\/NEJMoa1615664"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mercep I, Strikic D, Hrabac P, Pecin I, Reiner Z. PCSK9 inhibition: from effectiveness to cost-effectiveness. Front Cardiovasc Med 11: 1339487, 2024.","DOI":"10.3389\/fcvm.2024.1339487"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cutlip DE, Kereiakes DJ, Mauri L, Stoler R, Dauerman HL, Investigators E. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 8: 404-410, 2015.","DOI":"10.1016\/j.jcin.2014.10.017"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Adriaenssens T, Joner M, Godschalk TC, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 136: 1007-1021, 2017.","DOI":"10.1161\/CIRCULATIONAHA.117.026788"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Im E, Hong SJ, Ahn CM, et al. Long-term clinical outcomes of late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation. J Am Heart Assoc 8: e011817, 2019.","DOI":"10.1161\/JAHA.118.011817"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Suh Y, Kim BK, Shin DH, et al. Impact of statin treatment on strut coverage after drug-eluting stent implantation. Yonsei Med J 56: 45-52, 2015.","DOI":"10.3349\/ymj.2015.56.1.45"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Razzi F, Dijkstra J, Hoogendoorn A, et al. Plaque burden is associated with minimal intimal coverage following drug-eluting stent implantation in an adult familial hypercholesterolemia swine model. Sci Rep 13: 10683, 2023.","DOI":"10.1038\/s41598-023-37690-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Liu Z, Deng C, Zhao R, et al. Association of LDL-C level with neoatherosclerosis and plaque vulnerability in patients with late restenosis: an optical coherence tomography study. Int J Cardiovasc Imaging 39: 2609-2619, 2023.","DOI":"10.1007\/s10554-023-02956-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Moller JE, Engstrom T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 390: 1382-1393, 2024.","DOI":"10.1056\/NEJMc2406255"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation 139: e1046-e1081, 2019.","DOI":"10.1161\/CIR.0000000000000698"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mach F, Koskinas KC, Roeters van Lennep JE, et al.; ESC\/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46: 4359-4378, 2025.","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kodera S, Morita H, Kiyosue A, Ando J, Takura T, Komuro I. Cost-effectiveness of PCSK9 inhibitor plus statin in patients with triple-vessel coronary artery disease in Japan. Circ J 82: 2602-2608, 2018.","DOI":"10.1253\/circj.CJ-17-1455"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takahashi Y, Morimoto T, Iekushi K, Arai H. A medical claims database study of factors associated with medication adherence and treatment persistence in patients receiving PCSK9 monoclonal antibodies. J Atheroscler Thromb 32: 163-175, 2025.","DOI":"10.5551\/jat.64848"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Toda M, Iekushi K, Takahashi Y, Kohsaka S. Preferences for injectable lipid-lowering therapies in Japanese patients with atherosclerotic cardiovascular disease: findings from a Japanese cross-sectional study. Adv Ther 42: 4933-4949, 2025.","DOI":"10.1007\/s12325-025-03321-5"},{"key":"16","unstructured":"16. Schwartz GG, Szarek M, Reijnders E, et al. Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome. Eur J Prev Cardiol. Forthcoming."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356: 148-156, 2007.","DOI":"10.1056\/NEJMoa061189"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 383: 711-720, 2020.","DOI":"10.1056\/NEJMoa2004215"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Harada-Shiba M, Arai H, Ohmura H, et al. Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022. J Atheroscler Thromb 30: 558-586, 2023.","DOI":"10.5551\/jat.CR005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387-2397, 2015.","DOI":"10.1056\/NEJMoa1410489"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6453-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:11:33Z","timestamp":1786767093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/16\/65_6453-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6453-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"article-number":"6453-25"}}